Centessa Pharmaceuticals (CNTA)
| Bid | 11.5 |
| Market Cap | 1.8B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -235.74M |
| EPS (ttm) | -2.06 |
| PE Ratio (ttm) | -6.59 |
| Forward PE | -8.21 |
| Analyst | Buy |
| Ask | 16 |
| Volume | 371,561 |
| Avg. Volume (20D) | 1,038,128 |
| Open | 13.42 |
| Previous Close | 13.61 |
| Day's Range | 13.42 - 13.84 |
| 52-Week Range | 7.75 - 19.09 |
| Beta | 1.54 |
About CNTA
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatm...
Analyst Forecast
According to 8 analyst ratings, the average rating for CNTA stock is "Buy." The 12-month stock price forecast is $28, which is an increase of 106.19% from the latest price.
Stock Forecasts
4 months ago · seekingalpha.com
Centessa: Shift In Focus With ORX750 Development Continues To Pay OffCentessa Pharmaceuticals shelved its SerpinPC candidate, which was being used to treat patients with Hemophilia B; Established net savings of $200 million because of this move. Positive interim and fi...